Treatment > Irinotecan (CPT-11)


Astrocytic Tumorss


Michael L. Gruber, Deborah B Gruber
Phase II Treatment of Recurrent Malignant Astrocytoma with Temozolomide and Irinotecan

ASCO Proceedings, 2001 Annual Meeting, Abstract No. 2043

Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
J Clin Oncol. 2008 Jan 10;26(2):271-8
 Abstract |
DBLinks | BL 7:6


Glioblastoma


A. A. Brandes, A. Tosoni, M. Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S. Monfardini, M. Ermani
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1516

Chamberlain MC
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J Clin Oncol. 2008 Feb 20;26(6):1012-1013
 Abstract |  Full Text |  Reprint |
DBLinks | BL 7:5

Chamberlain MC
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme
J Neurooncol 2002 Jan;56(2):183-8


Chowdhary S, Wong ET
Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme-improvement over available therapy?
Nat Clin Pract Neurol. 2008 Jan 22. [Epub ahead of print]
Abstract | DBLinks | BL 7:3

K. A. Jaeckle, K. V. Ballman, P. Schomberg, J. Uhm, B. Schiethauer, C. Giannini, S. Felton, P. Brown, B. C. Jan NCCTG
N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG) study
2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1514. 
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1514


Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
Neuro Oncol. 2008 Feb 26; [Epub ahead of print]
 Abstract |
DBLinks | BL 7:6

James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friedman
In Reply
Journal of Clinical Oncology, Vol 26, No 6 (February 20), 2008: pp. 1013. DOI: 10.1200/JCO.2007.15.1746
 Abstract |  Full Text |  Reprint | DBLinks | BL 7:5

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
J Clin Oncol. 2007 Oct 20;25(30):4722-9.
Abstract | Full Text | Reprint | DBLinks

Yinglin Wang, Linda M. Liau, Timothy F. Cloughesy, Paul S. Mischel
p53 status determines the cell fate of glioblastoma cells in response to SN-38
Proceedings of the AACR, Volume 44, 2nd ed., July 2003, Abstract No. 2683


Glioma (High-Grade)


W. Adler, F. C. Lee
A phase I trial using combination irinotecan and thalidomide for recurrent CNS tumors
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 489

Mary L Affronti, David Reardon, Deborah Allen, Rodney Beason, Sridharan Gururangan, Allan Friedman, James Herndon, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Amy Walker, Darell D Bigner, Henry Friedman
A phase II study of CPT-11 plus BCNU for adults with high grade glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No.
2091  


M. A. Badruddoja, D. Reardon, R. Beason, A. Friedman, J. A. Quinn, J. Rich, J. Sampson, V. Stafford-Fox, D. D. Bigner, H. S. Friedman
Phase 1 study of temozolomide plus irinotecan (CPT-11) in adults with recurrent malignant glioma
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 409 

Tracy T. Batchelor, Mark R. Gilbert, Jeffrey G. Supko, Kathryn A. Carson, Louis B. Nabors, Stuart A. Grossman, Glenn J. Lesser, Tom Mikkelsen, and Surasak Phuphanich
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
Neuro-Oncology, January 2004, Volume 6 Number 1, Pages 21 -- 27 (Abstract+)

J Buckner, J Reid, L Schaaf, S Cha, K Wright, R Marks, M Wiesenfeld, A Hatfield, J Krook, S Nair, P Schaefer, L Miller
A Phase II Trial of Irinotecan (CPT-11) in Recurrent Glioma

ASCO Proceedings, 2000 Annual Meeting, Abstract No. 679A 


Lynn G. Feun, Angela Marini, Howard Landy, Arnold Markoe, Deborah Heros, Carlos Robles, Cristina Herrera and Niramol Savaraj
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors
J Neurooncol. 2006 Oct 19; [Epub ahead of print]
Abstract

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME
O6-benzylguanine-mediated enhancement of chemotherapy
Mol Cancer Ther 2002 Sep;1(11):943-8

Allan H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason, Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman
Novel use of Gliadel for gliomas

38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 2109

Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL
Irinotecan therapy in adults with recurrent or progressive malignant glioma

J Clin Oncol 1999 May;17(5):1516-25 

M. R. Gilbert, P. Wen, F. Lieberman, I. Robins, M. Mehta, W. K. A. Yung, S. Chang, L. Junck, T. Cloughesy, M. Prados
Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) study
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 410

R. V. Larocca, A. Cervera, J. B. Hargis, S. D. Glisson, G. H. Goldsmith, M. A. M. Laureano, B. Foreman
High-dose (HD) irinotecan in patients with recurrent unresectable high-grade gliomas on glucoronidation-enhancing anticonvulsants (GEACs): A phase I/II study
40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1578

Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, Deangelis LM, Robins IH, Aldape KD, Yung WK
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
Clin Cancer Res. 2007 Dec 1;13(23):7133-8
Abstract |
DBLinks

Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma
J Neurooncol. 2004 Feb;66(3):365-75. (Abstract+)

Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft
Clin Cancer Res 2000 Oct;6(10):4154-7 (
PDF Full Text)

Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J; North American Brain Tumor Consortium study
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Neuro-oncol. 2004 Jan;6(1):44-54. (Abstract+)

Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, James M. Provenzale, Amy Walker, Holly Schweitzer, Darell D. Bigner, Sandra Tourt-Uhlig, James E. Herndon II, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Cindy Bohlin, Christy Lentz, Henry S. Friedman
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Neuro-Oncology, Volume 6, Number 2, Pages 145 – 153. (Abstract+)

David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, Amy Walker, Michael Badruddoja, Sandra Tourt-Uhlig, James E. Herndon II, Jeannette M. Dowell, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Steven Silverman, Cindy Bohlin, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
Neuro-Oncology, April 2004, Volume 6, Number 2, Pages 134 – 144. (Abstract+)

R. Stupp, S. Ostermann, A. Calderoni, C. Uhlmann, S. Leyvraz
Temozolomide (TMZ) and irinotecan (CPT-11) for primary brain tumors. A dose escalation study
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 415

Sandra Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason, Brandon Evans, Sridharan Gururangan, Allan Friedman, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman
Treatment of adults with recurrent malignant glioma using temozolomide plus CPT-11: a phase I study

38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 2096

J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, A. Friedman
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 1506


Non-Nervous System Tumors


Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer
Cancer Chemother Pharmacol 2003 Apr 9; [epub ahead of print] 


Pediatric Brain Tumors


Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM.
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
J Clin Oncol. 2007 Oct 10;25(29):4622-7.
Abstract


Topoisomerase I inhibitors


Ewesuedo RB, Ratain MJ
Topoisomerase I Inhibitors
Oncologist 1997;2(6):359-364 (PDF Full Text)

 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
|
Children's Corner | E-mail Alerts | Journals | Newsletter | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP